Dr. Plotkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St Yaw 9
Brain Tumor Center Neuro-Oncology
Boston, MA 02114Phone+1 617-724-8770Fax+1 617-724-8769- Is this information wrong?
Education & Training
- Massachusetts General HospitalFellowship, Neuro-Oncology, 2002 - 2003
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1999 - 2002
- Tulane UniversityInternship, Internal Medicine, 1998 - 1999
- Tulane University School of MedicineClass of 1998
Certifications & Licensure
- NH State Medical License 2023 - 2025
- MA State Medical License 2002 - 2025
- LA State Medical License 2002 - 2002
- American Board of Psychiatry and Neurology Neurology
- United council of neurological subspecialtiesNeuro-Oncology
Clinical Trials
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Start of enrollment: 2008 Mar 01
- Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
- Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.Fertitta, L., Bergqvist, C., Sarin, K., Plotkin, S., Moertel, C., Petersen, A., Cannon, A., Berman, Y., Pichard, D., Röhl, C., Lessing, A., Brizion, B., Peiffer, B., R...> ;The British Journal of Dermatology. 2024 Jan 23
- Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.Patricia Richey, Margaret Funk, Fernanda Sakamoto, Scott Plotkin, Ina Ly, Justin Jordan, Alona Muzikansky, Josh Roberts, William Farinelli, Yakir Levin, Lilit Garibyan...> ;Journal of the American Academy of Dermatology. 2024 Apr 1
- Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.Verena Staedtke, Kara Anstett, David Bedwell, Marco Giovannini, Kim Keeling, Robert Kesterson, YooRi Kim, Bruce Korf, André Leier, Miranda L McManus, Herb Sarnoff, Jer...> ;Clinical Trials. 2024 Feb 1
- Join now to see all
Journal Articles
- Increasing Access to Specialty Care for Rare Diseases: A Case Study Using a Foundation Sponsored Clinic Network for Patients with Neurofibromatosis 1, Neurofibromatosi...Scott R Plotkin, Justin T Jordan, BioMed Central
Press Mentions
- University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical TrialJune 1st, 2022
- Wayne Biopharma Firm Targeting Rare Genetic Disorders Raises $6MMay 1st, 2020
- Antiangiogenesis Treatment Improves Hearing in Some NF2 PatientsJuly 8th, 2009
- Join now to see all
Grant Support
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1995–1997
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1994
Professional Memberships
- Member
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Industry Relationships
- Co-Founder, NF2 Therapeutics
- Co-Founder, NFlection Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: